Skip to main content

Advertisement

SpringerLink
Log in

From liver cirrhosis to HCC

  • MEET THE EXPERT
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

Hepatocellular carcinoma represents the main cause of death in patients with Child-A cirrhosis. Surveillance programs aimed at the early diagnosis of hepatocellular carcinoma, at potentially treatable stages, are mandatory in Child-A cirrhotic patients and in Child-B cirrhotic patients, provided liver transplantation can be pursued. Surveillance allows stage migration and in definite subgroups of patients, it improves survival as well. Even though several circulating markers have been tested, none of them, including serum AFP determination, is actually recommended in the setting of surveillance. Thus ultrasound scan is the only recommended test, and it should be performed at 6-month intervals. Upon detection of a new nodule, a diagnostic algorithm based on the size of the nodule should be applied. In the western countries, the BCLC proposal is the most widely used and validated staging system and it helps to choice of the best treatment option even though each patient deserves a multidisciplinary evaluation due to the complexity of the coexistence of two diseases: hepatocellular carcinoma and liver cirrhosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

AASLD:

American Association for the Study of Liver Diseases

CT:

Computerized tomography

HCC:

Hepatocellular carcinoma

RCT:

Randomized controlled trial

RM:

Magnetic resonance

US:

Ultrasound scan

References

  1. Laurent-Puig P, Zucman-Rossi J (2006) Genetics of hepatocellular tumors. Oncogene 25:3778–3786

    Article  PubMed  CAS  Google Scholar 

  2. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, Thung S, Mazzaferro V, Bruix J, Bottinger E, Friedman S, Waxman S, Llovet JM (2007) Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 45:938–947

    Article  PubMed  CAS  Google Scholar 

  3. Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, Bolondi L, Negrini M (2008) MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 12(6A):2189–2204

    Article  PubMed  CAS  Google Scholar 

  4. Nishida N, Nishimura T, Nagasaka T, Ikai I, Goel A, Boland CR (2007) Extensive methylation is associated with beta-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis. Cancer Res 67:4586–4594

    Article  PubMed  CAS  Google Scholar 

  5. Wulfkuhle JD, Liotta LA, Petricoin EF (2003) Proteomic applications for the early detection of cancer. Nat Rev Cancer 3:267–275

    Article  PubMed  CAS  Google Scholar 

  6. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M (1998) Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28:68–77

    Article  PubMed  CAS  Google Scholar 

  7. Poon RT, Fan ST, Wong J (2003) Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches. Ann Surg 238:9–28

    PubMed  Google Scholar 

  8. Bruix J, Sherman M, AASLD practice guideline (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022

    Article  PubMed  Google Scholar 

  9. Welch HG, Schwartz LM, Woloshin S (2000) Are increasing 5-year survival rates evidence of success against cancer? JAMA 283:2975–2978

    Article  PubMed  CAS  Google Scholar 

  10. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F et al (2001) Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48:251–259

    Article  PubMed  CAS  Google Scholar 

  11. McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F, Dunaway E et al (2000) Screening for hepatocellular carcinoma in Alaska natives infected with chronic Hepatitis B: a 16-year population-based study. Hepatology 32:842–846

    Article  PubMed  CAS  Google Scholar 

  12. Wong LL, Limm WM, Severino R, Wong LM (2000) Improved survival with screening for hepatocellular carcinoma. Liver Transpl 6:320–325

    Article  PubMed  CAS  Google Scholar 

  13. Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, Kobayashi K (1990) Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 12:680–687

    Article  PubMed  CAS  Google Scholar 

  14. Zhang BH, Yang BH, Tang ZY (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130:417–422

    PubMed  Google Scholar 

  15. Naimark D, Naigle G, Detsky AS (1994) The meaning of life expectancy: what is a clinically significant gain? J Gen Intern Med 9:702–707

    Article  PubMed  CAS  Google Scholar 

  16. Laupacis A, Feeny D, Detsky AS, Tugwell PX (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 146:473–481

    CAS  Google Scholar 

  17. Sarasin FP, Giostra E, Hadengue A (1996) Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 101:422–434

    Article  PubMed  CAS  Google Scholar 

  18. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB (2003) Screening for hepatocellular carcinoma in patients with Hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 98:679–690

    Article  PubMed  Google Scholar 

  19. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139:817–823

    PubMed  Google Scholar 

  20. Angulo P, Lindor KD (2002) Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 17(Suppl):S186–S190

    Article  PubMed  Google Scholar 

  21. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr (2001) International trends and patterns of primary liver cancer. Int J Cancer 94:290–296

    Article  PubMed  CAS  Google Scholar 

  22. Bolondi L (2003) Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 39:1076–1084

    Article  PubMed  Google Scholar 

  23. Solmi L, Primerano AM, Gandolfi L (1996) Ultrasound follow-up of patients at risk for hepatocellular carcinoma: results of a prospective study on 360 cases. Am J Gastroenterol 91(6):1189–1194

    PubMed  CAS  Google Scholar 

  24. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, Fujimoto I, Inoue A, Yamazaki H et al (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328(25):1797–1801

    Article  PubMed  CAS  Google Scholar 

  25. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY et al (2008) Associations between Hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 100:1134–1143

    Article  PubMed  CAS  Google Scholar 

  26. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, But DY et al (2009) Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic Hepatitis B. J Hepatol 50:80–88

    Article  PubMed  Google Scholar 

  27. Donato MF, Arosio E, Del Ninno E, Ronchi G, Lampertico P, Morabito A, Balestrieri MR, Colombo M (2001) High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity. Hepatology 34(3):523–528

    Article  PubMed  CAS  Google Scholar 

  28. Trerè D, Borzio M, Roncalli M, Derenzini M (1997) Hepatocyte AgNOR protein quantitative expression is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Eur J Histochem 41(Suppl 2):149–150

    PubMed  Google Scholar 

  29. Roberts LR, Gores GJ (2005) Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 25(2):212–225 Review

    Article  PubMed  CAS  Google Scholar 

  30. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR et al (2010) Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 138:493–502

    Article  PubMed  CAS  Google Scholar 

  31. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson, El-Kamary SS, Bass EB (2002) Screening tests for hepatocellular carcinoma in patients with chronic Hepatitis C: a systematic review. Hepatology 36((5 Suppl 1)):S84–S92 Review

    Article  PubMed  Google Scholar 

  32. Gambarin-Gelwan M, Wolf DC, Shapiro R, Schwartz ME, Min AD (2000) Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol 95(6):1535–1538

    Article  PubMed  CAS  Google Scholar 

  33. Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, Brown JJ, McFarland EG, Middleton WD, Balfe DM, Ritter JH (2003) Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 226(2):533–542

    Article  PubMed  Google Scholar 

  34. Trevisani F, De NS, Rapaccini G, Farinati F, Benvegnu L, Zoli M, Grazi GL et al (2002) Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient serviva (Italian experience). Am J Gastroenterol 97:734–744

    Article  PubMed  Google Scholar 

  35. Sato Y, Sekine T, Ohwada S (1994) Alpha-fetoprotein-producing rectal cancer: calculated tumor marker doubling time. J Surg Oncol 55:265–268

    Article  PubMed  CAS  Google Scholar 

  36. Adachi Y, Tsuchihashi J, Shiraishi N, Yasuda K, Etoh T, Kitano S (2003) AFP-producing gastric carcinoma: multivariate analysis of prognostic factors in 270 patients. Oncology 65:95–101

    Article  PubMed  CAS  Google Scholar 

  37. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, Boix L et al (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47:97–104

    Article  PubMed  Google Scholar 

  38. Leoni S, Piscaglia F, Golfieri R, Camaggi V, Vidili G, Pini P, Bolondi L (2010) The Impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 105:599–609

    Article  PubMed  Google Scholar 

  39. Vilana R, Forner A, Bianchi L, Garcia-Criado A, Rimola J, Rodrıguez de Lope C et al (2010) Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 51:2020–2029

    Article  PubMed  Google Scholar 

  40. International consensus group (2009) Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49:658–664

    Article  Google Scholar 

  41. Colecchia A, Scaioli E, Montrone L, Vestito A, Di Biase AR, Pieri M, D’Errico-Grigioni A, Bacchi-Reggiani ML, Ravaioli M, Grazi GL, Festi D (2011) Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. J Hepatol 54(2):300–305

    Article  PubMed  Google Scholar 

  42. Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Yamamoto J, Shimada K, Kosuge T et al (1998) Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 28:1241–1246

    Article  PubMed  CAS  Google Scholar 

  43. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11):693–699

    Article  PubMed  CAS  Google Scholar 

  44. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, Investigators Study Group SHARP (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Digestive Diseases and Internal Medicine, University of Bologna-Policlinico S. Orsola Malpighi Bologna, Via Albertoni, 15, 40138, Bologna, Italy

    Luigi Bolondi & Laura Gramantieri

Authors
  1. Luigi Bolondi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Gramantieri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luigi Bolondi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bolondi, L., Gramantieri, L. From liver cirrhosis to HCC. Intern Emerg Med 6 (Suppl 1), 93 (2011). https://doi.org/10.1007/s11739-011-0682-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11739-011-0682-8

Keywords

Search

Navigation